We're available 24/7. Call us anytime. (888) 552-6760
(888) 552-6760 SCHEDULE AN APPOINTMENT

Andrew Saul Artz,

Hematologist-Oncologist

Biography photo
Location
Duarte Comprehensive Cancer Center
1500 East Duarte Road
Duarte, CA 91010
Specialties
Hematologic Oncology
Education
Medical school:
Board Certifications

  • 2005-Present, Medical Oncology, American Board of Internal Medicine

  • 2005-Present, Hematology, American Board of Internal Medicine

  • 2000-2010, Internal Medicine, American Board of Internal Medicine

  • 2001-Present, Medical License, State of Illinois. License number 36103920

Degrees

  • 2002-2004, Masters of Science for Clinical Professionals, Department of Health Studies, University of Chicago, Chicago, Illinois

  • 1993-1997, M.D., West Virginia University, Morgantown, West Virginia

  • 1988-1992, B.A., Molecular Biology, University of Colorado, Boulder, Colorado

Fellowship

  • 2001-2004, Fellowship in Hematology and Oncology, University of Chicago, Chicago, Illinois

Residency

  • 1997-2000, Internal Medicine Residency, Georgetown University, Washington, DC

Professional Experience

  • 2021-present, Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California

  • 2019-present, Director, Aging and Blood Cancers Program, City of Hope, Duarte, CA

  • 2019-present, Deputy Director of Outcomes, Center for Cancer and Aging, City of Hope, Duarte, CA

  • 2019-2021, Associate Clinical Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California

  • 2014-2019, Associate Professor, Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

  • 2007-2013, Assistant Professor, Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

  • 2005-2007, Instructor, Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

Academic Appointments
  • Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
  • Director, Aging and Blood Cancers Program
  • Deputy Director of Outcomes, Center for Cancer and Aging
About Me
I cherish the bonds formed with patients and their families.
 
Andrew Artz, M.D., M.S., has spent decades tending to the special needs of older people battling leukemia and blood diseases. An acknowledged leader in the field, he has created unique, multidisciplinary programs to put his senior patients in the best possible condition before they receive lifesaving stem cell transplants. He also has led research to better understand and treat anemia in older persons.

Dr. Artz received his medical degree in his home state at West Virginia University in Morgantown, West Virginia. Medicine residency was completed at Georgetown University in Washington, D.C., followed by hematology/oncology fellowship at the University of Chicago then six months of transplant training as a visiting physician at the Fred Hutchinson Cancer Center in Seattle. He was an attending hematologist and clinical director of the transplant program at the University of Chicago before moving to City of Hope.
 
At City of Hope, Dr. Artz directs the Aging and Blood Cancers Program. “When I first came to City of Hope,” he says, “I could feel the energy and optimism coursing through the blood of the institution, uniformly committed to eradicating cancer. I feel fortunate to be at City of Hope.”
Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.